Condition: NonSegmental Vitiligo · Sponsor: Incyte Corporation
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Psoriahue | Buenos Aires, Argentina | Recruiting |
| Hospital Italiano de Buenos Aires | Buenos Aires, Argentina | Recruiting |
| Instituto de Neumonologia Y Dermatologia | Buenos Aires, Argentina | Recruiting |
| Consultorios Medicos Dr. Doreski | Buenos Aires, Argentina | Recruiting |
| Derma Internacional S.A. | Buenos Aires, Argentina | Recruiting |
| Hospital Universitario Austral | Derqui-pilar, Argentina | Recruiting |
| Centro de Investigaciones Medicas Mar Del Plata | Mar del Plata, Argentina | Recruiting |
| Hospital Del Nino Jesus | San Miguel de Tucumán, Argentina | Recruiting |
| Universitaetsklinikum Graz | Graz, Austria | Recruiting |
| Medical University Innsbruck | Innsbruck, Austria | Recruiting |
| Hopital Universitaire de Bruxelles (Academisch Ziekenhuis Brussel) | Brussels, Belgium | Recruiting |
| Universitair Ziekenhuis Gent | Ghent, Belgium | Recruiting |
+ 67 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06804811